Cardiovascular risk assessment is becoming increasingly important in an era of personalised therapy. In this short podcast, Professor Steve Nissen – in conversation with Professor Stephen Nicholls and Professor Sophia Zoungas – explains what is needed to advance the concept of polygenic risk and make it clinically-useful. They also discuss how incentives could bolster the number of women in cardiovascular clinical trials.

This is an excerpt from a recent Amgen One Cardiovascular Academy live webcast, hosted by Professor Stephen Nicholls (MonashHeart), in conversation with Professor Steven Nissen (The Cleveland Clinic, Ohio, USA) and Professor Sophia Zoungas (Head of Monash University’s School of Public Health and Preventive Medicine).

the limbic · CV risk reduction: current status and future directions
Amgen One Cardiovascular Academy educational agenda is developed by an independent steering committee comprising Professor Stephen Nicholls, MonashHeart, VIC (Chair), Professor Gemma Figtree, Royal North Shore Hospital, NSW, Professor Anthony Keech, Royal Prince Alfred Hospital, NSW, Professor Karam Kostner, Mater Hospital, QLD, Professor Richard O’Brien, Austin Hospital, VIC, Associate Professor David Sullivan, Royal Prince Alfred Hospital, NSW, Professor Gerald Watts, University of Western Australia, WA and Professor Sophia Zoungas, Monash University, VIC.